Medicine

Medicine Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin dependent kinase 4 and 6 CDK4 6

Explore the current issue of The New England Journal of Medicine Vol 393 No 21 Imlunestrant is a next generation brain penetrant oral selective estrogen receptor ER degrader that delivers continuous ER inhibition even in cancers with mutations in the

[img_alt-1]

Medicine

[img_alt-2]

[img_title-2]

[img_alt-3]

[img_title-3]

Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event free survival in patients with resectable non small cell lung Semaglutide at a dose of 2 4 mg has established weight loss and cardiovascular benefits and cagrilintide at a dose of 2 4 mg has shown promising results in early phase trials

Throughout the course of multiple sclerosis gradually progressive neurologic impairment can occur which has been called disability accrual Current disease modifying Obinutuzumab a humanized type II anti CD20 monoclonal antibody provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus

More picture related to Medicine

[img_alt-4]

[img_title-4]

[img_alt-5]

[img_title-5]

[img_alt-6]

[img_title-6]

Tirzepatide and semaglutide are highly effective medications for obesity management The efficacy and safety of tirzepatide as compared with semaglutide in adults In bronchiectasis neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression Brensocatib an oral reversible inhibitor of dipeptidyl

[desc-10] [desc-11]

[img_alt-7]

[img_title-7]

[img_alt-8]

[img_title-8]

First Line Camizestrant For Emerging ESR1 Mutated Advanced

https://www.nejm.org › doi › full
Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin dependent kinase 4 and 6 CDK4 6

Get More Here!!